NO20063711L - Moraxella Catarrhalis ytre membran protein-106 polypeptid, gensekvens og anvendelser derav - Google Patents

Moraxella Catarrhalis ytre membran protein-106 polypeptid, gensekvens og anvendelser derav

Info

Publication number
NO20063711L
NO20063711L NO20063711A NO20063711A NO20063711L NO 20063711 L NO20063711 L NO 20063711L NO 20063711 A NO20063711 A NO 20063711A NO 20063711 A NO20063711 A NO 20063711A NO 20063711 L NO20063711 L NO 20063711L
Authority
NO
Norway
Prior art keywords
polypeptide
membrane protein
outer membrane
gene sequence
catarrhali
Prior art date
Application number
NO20063711A
Other languages
English (en)
Inventor
Kenneth Tucker
Laura Plosila
Original Assignee
Antex Biolog Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Publication of NO20063711L publication Critical patent/NO20063711L/no
Application filed by Antex Biolog Inc filed Critical Antex Biolog Inc

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/195—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria
    • C07K14/21—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria from Pseudomonadaceae (F)
    • C07K14/212—Moraxellaceae, e.g. Acinetobacter, Moraxella, Oligella, Psychrobacter
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/12—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from bacteria
    • C07K16/1203—Gram-negative bacteria
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/12—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from bacteria
    • C07K16/1203—Gram-negative bacteria
    • C07K16/1214—Pseudomonadaceae (F)
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/12—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from bacteria
    • C07K16/1203—Gram-negative bacteria
    • C07K16/1217—Neisseriaceae (F)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C07K2317/734—Complement-dependent cytotoxicity [CDC]
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Immunology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Public Health (AREA)
  • Communicable Diseases (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Oncology (AREA)
  • Veterinary Medicine (AREA)
  • General Chemical & Material Sciences (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)

Abstract

Det er beskrevet Moz-oxe/Zo catarrhalis ytre membran protein-106 (OMP106) polypeptid, nukleotidsekvenser som koder for nevnte polypeptider og antistoffer som spesifikt binder OMP106 polypeptidet. Det er også beskrevet immunogene, profylaktiske eller terapeutiske sammensetninger, innbefattende vaksiner, omfattende OMP106 polypeptidet og anvendelse av OMP106 polypeptidet for fremstilling av et medikament for behandling M catarrhalis infeksjoner.
NO20063711A 1996-05-03 2006-08-18 Moraxella Catarrhalis ytre membran protein-106 polypeptid, gensekvens og anvendelser derav NO20063711L (no)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US08/642,712 US7341727B1 (en) 1996-05-03 1996-05-03 M. catarrhalis outer membrane protein-106 polypeptide, methods of eliciting an immune response comprising same
PCT/US1997/007679 WO1997041731A1 (en) 1996-05-03 1997-04-28 Moraxella catarrhalis outer membrane protein-106 polypeptide, gene sequence and uses thereof

Publications (1)

Publication Number Publication Date
NO20063711L true NO20063711L (no) 1998-12-28

Family

ID=24577687

Family Applications (2)

Application Number Title Priority Date Filing Date
NO19985113A NO324816B1 (no) 1996-05-03 1998-11-02 Moraxella Catarrhalis ytre membran protein-106 polypeptid, og fragment av dette, DNA som koder for polypeptidet, antistoffer og vaksiner, samt anvendelse av peptidene til fremstilling av et medikament for behandling av infeksjoner.
NO20063711A NO20063711L (no) 1996-05-03 2006-08-18 Moraxella Catarrhalis ytre membran protein-106 polypeptid, gensekvens og anvendelser derav

Family Applications Before (1)

Application Number Title Priority Date Filing Date
NO19985113A NO324816B1 (no) 1996-05-03 1998-11-02 Moraxella Catarrhalis ytre membran protein-106 polypeptid, og fragment av dette, DNA som koder for polypeptidet, antistoffer og vaksiner, samt anvendelse av peptidene til fremstilling av et medikament for behandling av infeksjoner.

Country Status (25)

Country Link
US (6) US7341727B1 (no)
EP (1) EP0900025B1 (no)
JP (2) JP4401437B2 (no)
CN (2) CN100415871C (no)
AR (1) AR006999A1 (no)
AT (1) ATE244016T1 (no)
AU (1) AU723528B2 (no)
BG (1) BG64832B1 (no)
BR (1) BR9711090A (no)
CA (1) CA2253636C (no)
CZ (1) CZ298034B6 (no)
DE (1) DE69723254T2 (no)
EA (1) EA002743B1 (no)
EE (1) EE04684B1 (no)
ES (1) ES2202624T3 (no)
GE (1) GEP20022695B (no)
HU (1) HU223004B1 (no)
NO (2) NO324816B1 (no)
NZ (1) NZ332896A (no)
PL (3) PL189995B1 (no)
SK (1) SK284812B6 (no)
TW (1) TW541314B (no)
UA (1) UA68332C2 (no)
WO (1) WO1997041731A1 (no)
ZA (1) ZA973809B (no)

Families Citing this family (71)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6440425B1 (en) * 1995-05-01 2002-08-27 Aventis Pasteur Limited High molecular weight major outer membrane protein of moraxella
US6335018B1 (en) * 1995-05-01 2002-01-01 Aventis Pasteur Limited High molecular weight major outer membrane protein of moraxella
US7341727B1 (en) * 1996-05-03 2008-03-11 Emergent Product Development Gaithersburg Inc. M. catarrhalis outer membrane protein-106 polypeptide, methods of eliciting an immune response comprising same
AUPO652897A0 (en) 1997-04-30 1997-05-29 University Of Melbourne, The Synthetic peptide constructs for the diagnosis and treatment of periodontitis
GB9714276D0 (en) 1997-07-08 1997-09-10 Univ Dundee Peptides and related compounds
US8129500B2 (en) * 1997-12-10 2012-03-06 Csl Limited Porphyromonas gingivalis polypeptides and nucleotides
GB9808720D0 (en) 1998-04-23 1998-06-24 Smithkline Beecham Biolog Novel compounds
GB9810084D0 (en) 1998-05-11 1998-07-08 Cortecs Uk Ltd Proteins
GB9810193D0 (en) * 1998-05-12 1998-07-08 Smithkline Beecham Biolog Novel compounds
WO1999058682A2 (en) * 1998-05-12 1999-11-18 Smithkline Beecham Biologicals S.A. Compounds from moraxella catarrhalis
GB9810285D0 (en) 1998-05-13 1998-07-15 Smithkline Beecham Biolog Novel compounds
US6541616B1 (en) 1998-10-01 2003-04-01 Antex Biologics Inc. Moraxella catarrhalis protein, gene sequence and uses thereof
JP2002539273A (ja) 1999-03-19 2002-11-19 スミスクライン ビーチャム バイオロジカルズ ソシエテ アノニム ワクチン
US6673910B1 (en) 1999-04-08 2004-01-06 Genome Therapeutics Corporation Nucleic acid and amino acid sequences relating to M. catarrhalis for diagnostics and therapeutics
CA2374364A1 (en) * 1999-05-24 2000-11-30 Smithkline Beecham Biologicals S.A. Polypeptides and polynucleotides from moraxella catarrhalis
GB9915031D0 (en) * 1999-06-25 1999-08-25 Smithkline Beecham Biolog Novel compounds
GB9921691D0 (en) * 1999-09-14 1999-11-17 Smithkline Beecham Sa Novel compounds
AU1383901A (en) * 1999-09-14 2001-04-17 Smithkline Beecham Biologicals (Sa) Novel compounds
GB0022742D0 (en) 2000-09-15 2000-11-01 Smithkline Beecham Biolog Vaccine
GB0103171D0 (en) 2001-02-08 2001-03-28 Smithkline Beecham Biolog Vaccine composition
SE0102410D0 (sv) 2001-07-04 2001-07-04 Arne Forsgren Novel surface exposed immunoglobulin D-binding protein from moraxella catarrhalis
CA2493124C (en) 2002-08-02 2014-04-29 Glaxosmithkline Biologicals S.A. Vaccine
EP2425853A1 (en) 2005-04-08 2012-03-07 Wyeth LLC Multivalent Pneumococcal Polysaccharide-Protein Conjugate Composition
CN100357318C (zh) * 2005-10-11 2007-12-26 中山大学 美人鱼发光杆菌外膜蛋白w和编码序列及其制备方法和应用
TWI457133B (zh) 2005-12-13 2014-10-21 Glaxosmithkline Biolog Sa 新穎組合物
GB0607088D0 (en) 2006-04-07 2006-05-17 Glaxosmithkline Biolog Sa Vaccine
BRPI0620460B8 (pt) 2005-12-22 2021-05-25 Glaxosmithkline Biologicals Sa uso de composição imunogênica para bebês, e, processo para produzir uma vacina
EP1973933B1 (en) 2006-01-17 2020-06-24 Forsgren, Arne A NOVEL SURFACE EXPOSED HAEMOPHILUS INFLUENZAE PROTEIN (PROTEIN E; pE)
EP2038297A4 (en) * 2006-06-27 2010-03-03 Oral Health Australia Pty Ltd PORPHYROMONAS GINGIVALIS POLYPEPTIDES SUITABLE FOR PREVENTION OF PERIODONTITIS
BRPI0813644B8 (pt) 2007-06-26 2021-05-25 Glaxosmithkline Biologicals Sa composição imunogênica, vacina, processo para fabricar a mesma, e, uso da composição imunogênica ou vacina
NZ595378A (en) * 2007-07-12 2013-04-26 Immunology treatment for biofilms
WO2009006699A1 (en) 2007-07-12 2009-01-15 Oral Health Australia Pty Ltd Biofilm treatment
WO2009049013A2 (en) * 2007-10-09 2009-04-16 Tufts University Cholera vaccines
ES2633738T3 (es) 2008-08-29 2017-09-25 Oral Health Australia Pty Ltd Prevención, tratamiento y diagnóstico de la infección por p. gingivales
US8140041B2 (en) * 2009-08-27 2012-03-20 Mediatek Inc. Tunable capacitive device with linearization technique employed therein
ES2366735B1 (es) * 2009-10-08 2012-09-13 Fundación Pública Andaluza Para La Gestión De La Investigación En Salud De Sevilla Vacuna frente a acinetobacter baumannii.
CN102713621B (zh) 2009-11-23 2016-10-19 西维克公司 用于施行化验的方法和设备
US9759718B2 (en) 2009-11-23 2017-09-12 Cyvek, Inc. PDMS membrane-confined nucleic acid and antibody/antigen-functionalized microlength tube capture elements, and systems employing them, and methods of their use
US10065403B2 (en) 2009-11-23 2018-09-04 Cyvek, Inc. Microfluidic assay assemblies and methods of manufacture
US9855735B2 (en) 2009-11-23 2018-01-02 Cyvek, Inc. Portable microfluidic assay devices and methods of manufacture and use
US9651568B2 (en) 2009-11-23 2017-05-16 Cyvek, Inc. Methods and systems for epi-fluorescent monitoring and scanning for microfluidic assays
US9216412B2 (en) 2009-11-23 2015-12-22 Cyvek, Inc. Microfluidic devices and methods of manufacture and use
US9700889B2 (en) 2009-11-23 2017-07-11 Cyvek, Inc. Methods and systems for manufacture of microarray assay systems, conducting microfluidic assays, and monitoring and scanning to obtain microfluidic assay results
US9500645B2 (en) 2009-11-23 2016-11-22 Cyvek, Inc. Micro-tube particles for microfluidic assays and methods of manufacture
WO2013133899A1 (en) 2012-03-08 2013-09-12 Cyvek, Inc Microfluidic assay systems employing micro-particles and methods of manufacture
GB201003922D0 (en) 2010-03-09 2010-04-21 Glaxosmithkline Biolog Sa Conjugation process
GB201003924D0 (en) 2010-03-09 2010-04-21 Glaxosmithkline Biolog Sa Immunogenic composition
EP2544714A1 (en) 2010-03-10 2013-01-16 GlaxoSmithKline Biologicals S.A. Vaccine composition
NZ602892A (en) 2010-04-13 2014-08-29 Celldex Therapeutics Inc Antibodies that bind human cd27 and uses thereof
US8501197B2 (en) 2010-04-30 2013-08-06 The Research Foundation for The State of New York Compositions and methods for stimulating immune response against Moraxella catarrhalis
GB201103836D0 (en) 2011-03-07 2011-04-20 Glaxosmithkline Biolog Sa Conjugation process
RU2481401C2 (ru) * 2011-07-15 2013-05-10 Государственное образовательное учреждение высшего профессионального образования "Уральская государственная медицинская академия Министерства здравоохранения и социального развития Российской Федерации" (ГОУ ВПО УГМА Минздравсоцразвития России) СПОСОБ ВЫЯВЛЕНИЯ β-ЛАКТАМАЗОПРОДУЦИРУЮЩИХ ОКСИДАЗОПОЗИТИВНЫХ ГРАМОТРИЦАТЕЛЬНЫХ ДИПЛОКОККОВ, ПОДОЗРИТЕЛЬНЫХ НА ПРИНАДЛЕЖНОСТЬ К MORAХELLA (BRANCHAMELLA) CATARRHALIS
US11210432B2 (en) * 2013-08-20 2021-12-28 Janus Technologies, Inc. Method and apparatus for selectively snooping and capturing data for secure computer interfaces
EP3268037B1 (en) 2015-03-09 2022-08-31 Celldex Therapeutics, Inc. Cd27 agonists
GB201518684D0 (en) 2015-10-21 2015-12-02 Glaxosmithkline Biolog Sa Vaccine
US10228367B2 (en) 2015-12-01 2019-03-12 ProteinSimple Segmented multi-use automated assay cartridge
JP7038064B2 (ja) 2016-04-18 2022-03-17 セルデックス セラピューティクス インコーポレイテッド ヒトｃｄ４０に結合するアゴニスト抗体およびその使用
GB201621686D0 (en) 2016-12-20 2017-02-01 Glaxosmithkline Biologicals Sa Novel methods for inducing an immune response
GB2600654B (en) 2017-05-30 2022-11-02 Glaxosmithkline Biologicals Sa Novel devices
WO2019106192A1 (en) 2017-12-01 2019-06-06 Glaxosmithkline Biologicals Sa Saponin purification
WO2019204462A2 (en) 2018-04-17 2019-10-24 Celldex Therapeutics, Inc. Anti-cd27 and anti-pd-l1 antibodies and bispecific constructs
EP3833382A1 (en) 2018-08-07 2021-06-16 GlaxoSmithKline Biologicals S.A. Processes and vaccines
CN111157735B (zh) * 2018-11-07 2023-02-07 广州万孚生物技术股份有限公司 凝集性卡他莫拉菌单克隆抗体及其制备方法和应用
WO2020109365A1 (en) 2018-11-29 2020-06-04 Glaxosmithkline Biologicals Sa Methods for manufacturing an adjuvant
WO2020123444A1 (en) 2018-12-11 2020-06-18 Celldex Therapeutics, Inc. Methods of using cd27 antibodies as conditioning treatment for adoptive cell therapy
JP7640473B2 (ja) 2019-06-05 2025-03-05 グラクソスミスクライン バイオロジカルズ ソシエテ アノニム サポニン精製
CN111778226B (zh) * 2020-07-21 2022-04-05 东北师范大学 一种水稻耐碱胁迫相关的质膜H+-ATPase蛋白及其应用
EP4320159A1 (en) 2021-04-09 2024-02-14 Celldex Therapeutics, Inc. Antibodies against ilt4, bispecific anti-ilt4/pd-l1 antibody and uses thereof
WO2023077521A1 (en) 2021-11-08 2023-05-11 Celldex Therapeutics, Inc Anti-ilt4 and anti-pd-1 bispecific constructs
GB202205833D0 (en) 2022-04-21 2022-06-08 Glaxosmithkline Biologicals Sa Bacteriophage
EP4558170A1 (en) 2022-07-19 2025-05-28 GlaxoSmithKline Biologicals S.A. Continuous process for vaccine production

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4675176A (en) * 1983-12-12 1987-06-23 Norden Laboratories Moraxella bovis protease vaccine
US4879213A (en) * 1986-12-05 1989-11-07 Scripps Clinic And Research Foundation Synthetic polypeptides and antibodies related to Epstein-Barr virus early antigen-diffuse
US5552146A (en) * 1991-08-15 1996-09-03 Board Of Regents, The University Of Texas System Methods and compositions relating to useful antigens of Moraxella catarrhalis
US5607846A (en) 1994-05-17 1997-03-04 Research Foundation Of State University Of New York Vaccine for moraxella catarrhalis
US6440425B1 (en) 1995-05-01 2002-08-27 Aventis Pasteur Limited High molecular weight major outer membrane protein of moraxella
US6335018B1 (en) 1995-05-01 2002-01-01 Aventis Pasteur Limited High molecular weight major outer membrane protein of moraxella
US7341727B1 (en) * 1996-05-03 2008-03-11 Emergent Product Development Gaithersburg Inc. M. catarrhalis outer membrane protein-106 polypeptide, methods of eliciting an immune response comprising same
GB9809683D0 (en) 1998-05-06 1998-07-01 Smithkline Beecham Biolog Novel compounds
GB9812163D0 (en) 1998-06-05 1998-08-05 Smithkline Beecham Biolog Novel compounds

Also Published As

Publication number Publication date
CZ352498A3 (cs) 1999-06-16
US20100021492A1 (en) 2010-01-28
US7341727B1 (en) 2008-03-11
PL189374B1 (pl) 2005-07-29
HU223004B1 (hu) 2004-03-01
BG102983A (en) 2000-05-31
NO985113D0 (no) 1998-11-02
EA002743B1 (ru) 2002-08-29
CZ298034B6 (cs) 2007-05-30
US7914795B2 (en) 2011-03-29
ZA973809B (en) 1997-12-01
ES2202624T3 (es) 2004-04-01
PL189995B1 (pl) 2005-10-31
CN1222618C (zh) 2005-10-12
CN1223549A (zh) 1999-07-21
HK1021299A1 (en) 2000-06-09
NO324816B1 (no) 2007-12-10
EP0900025A1 (en) 1999-03-10
PL330935A1 (en) 1999-06-07
JP2008161194A (ja) 2008-07-17
US20070087019A1 (en) 2007-04-19
AU723528B2 (en) 2000-08-31
PL189375B1 (pl) 2005-07-29
GEP20022695B (en) 2002-05-27
EE04684B1 (et) 2006-08-15
AU3118097A (en) 1997-11-26
CA2253636C (en) 2003-04-22
DE69723254D1 (de) 2003-08-07
SK284812B6 (sk) 2005-12-01
BG64832B1 (bg) 2006-06-30
NO985113L (no) 1998-12-28
TW541314B (en) 2003-07-11
HUP9902695A3 (en) 2001-02-28
ATE244016T1 (de) 2003-07-15
WO1997041731A1 (en) 1997-11-13
US7128910B2 (en) 2006-10-31
US20020177200A1 (en) 2002-11-28
SK150998A3 (en) 1999-05-07
NZ332896A (en) 2000-05-26
CN100415871C (zh) 2008-09-03
CA2253636A1 (en) 1997-11-13
US6214981B1 (en) 2001-04-10
US7576179B2 (en) 2009-08-18
US20080145916A1 (en) 2008-06-19
CN1800359A (zh) 2006-07-12
EA199800973A1 (ru) 1999-06-24
BR9711090A (pt) 1999-08-17
EP0900025A4 (en) 2000-01-05
HK1095358A1 (zh) 2007-05-04
DE69723254T2 (de) 2004-04-22
AR006999A1 (es) 1999-10-13
UA68332C2 (en) 2004-08-16
EP0900025B1 (en) 2003-07-02
JP4401437B2 (ja) 2010-01-20
EE9800373A (et) 1999-04-15
JP2000510696A (ja) 2000-08-22
HUP9902695A2 (hu) 1999-12-28

Similar Documents

Publication Publication Date Title
GEP20022695B (en) Moraxella Catarrhalis Outer Membrane Protein-106 Polypeptide, Gene Sequence and Uses Thereof
DE69829668D1 (de) Herstellung und verwendung von rekombinanten influenza a virus m2 konstruktionen und impstoffe
DK0839196T3 (da) Humant CTLA-8 og anvendelser af CTLA-8-relaterede proteiner
CY1106806T1 (el) Dna και πολυπεπτιδια ανθρωπινης tslp
DK35593A (da) Polypeptid kodet af lav-dna-sekvens
HUP9901186A2 (hu) Peptid-és adjuvánsalapú gyógyszerkészítmény immunmodulációra
DK79190A (da) Praktisk taget rent polypeptid og dets anvendelse; rekombinantvirus, rekombinantvirus, rekomninant-dna-vektor og encellet organisme til dets fremstilling
NZ503763A (en) Antigenic compositions and vaccines comprising a high molecular weight (HMW) protein of Clamydia for therapeutic and prophylactic use
DK0703981T3 (da) Immunogene sammensætninger mod Helicobacterinfektion, polypeptider til anvendelse i sammensætningerne og nucleinsyresekvenser, som koder for nævnte polypeptider
NO912825L (no) Fremgangsmaate for fremstilling av kokonjugatvaksiner omfattende im munogent protein, hiv-beslektede peptider og anioniske grupper.
ZA936970B (en) Anti-feline immunodeficiency virus (FIV) vaccines
DK0996726T3 (da) T-celle-membranprotein (TIRC7), peptider og antistoffer afledt deraf og anvendelse deraf
NZ502626A (en) Vaccines comprising a nucleic acid vector encoding the G protein of respiratory syncytial virus (RSV)
AU1239997A (en) Polypeptides corresponding to the amino acid sequences of proteins p57 or p9.5 of Borna disease virus, nucleic acid fragments coding therefore and their use for diagnostic and immunization purposes
NO20011263L (no) Moraxella Catarrhalis BASBO34-polypeptider og anvendelser derav
AU7052191A (en) Antitumoral composition based on polypeptides having human interleukin 2 activity
DK1204752T3 (da) Immunogene polypeptider afledt fra Moraxella catarrhalis og anvendelser deraf
NO910331D0 (no) Rekombinant plasmid, fremgangsmaate til dets fremstilling og anvendelse av plasmidet i produksjonen av proteiner.
Mikulik et al. The elongation factor Tu of the extremely thermophilic hydrogen-oxidizing bacterium Calderobacterium hydrogenophilum.
HK1016424A (en) Protein-106 polypeptide of the outer membrane of moraxella catarrhalis, gene sequence and uses thereof
CA2143187A1 (en) Anti-feline immunodeficiency virus (fiv) vaccines
DE60035788D1 (de) Polypeptide aus moraxella (branhamella) catarrhalis
WO2001081535A3 (fr) Nouveau polypeptide, proteine pax humaine 9.9, et polynucleotide codant pour ce polypeptide

Legal Events

Date Code Title Description
FC2A Withdrawal, rejection or dismissal of laid open patent application